A $25T industry
China is the world's FinTech leader. This firm may transform a $25T industry.
See this firm now.
John F. Crowley, insider at Intellia Therapeutics
John F. Crowley Insider Alerts

Get notified the next time John F. Crowley buys or sells Intellia Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

John F. Crowley Insider Information

John F. Crowley is a visionary advocate and leader in advancing therapies for people living with rare diseases. Currently, he is the chairman and CEO of Amicus Therapeutics, a global biotechnology company focusing on developing treatments for rare genetic diseases. John has been Amicus’ chief executive since 2005 and has overseen the company’s growth from a four-person start-up to one with operations in more than 30 countries, with 500+ employees and a market value of more than $3 billion.

His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease, a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, John left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and chief executive of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease, which he credits as ultimately saving his children’s lives. In 2001, Novazyme was acquired by Genzyme Corporation (now Sanofi), and John continued to play a lead role in the development of a drug for Pompe disease as senior vice president at Genzyme.

He has held leadership roles at several nonprofits, including the Global Genes Project as a founding board member and the Make-A-Wish Foundation as a former national chairman. John also is a member of the University Council on Science & Technology at Notre Dame and a Henry Crown Fellow at the Aspen Institute. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame.

John graduated with a B.S. in Foreign Service from Georgetown University. He additionally earned a J.D. from the University of Notre Dame Law School and an MBA from Harvard Business School. John also served as a commissioned intelligence officer in the U.S. Navy Reserve for more than a decade, assigned to the U.S. Special Operations Command and is a combat veteran of the Global War on Terrorism, with service in Afghanistan.

What is John F. Crowley's net worth?

The estimated net worth of John F. Crowley is at least $112.72 million as of September 15th, 2021. Mr. Crowley owns 861,845 shares of Intellia Therapeutics stock worth more than $112,720,708 as of October 22nd. This net worth estimate does not reflect any other assets that Mr. Crowley may own. Learn More.

How do I contact John F. Crowley?

The corporate mailing address for Mr. Crowley and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]

Has John F. Crowley been buying or selling shares of Intellia Therapeutics?

During the past quarter, John F. Crowley has sold $1,604,275.00 in shares of Intellia Therapeutics stock. Most recently, John F. Crowley sold 2,500 shares of the business's stock in a transaction on Monday, October 11th. The shares were sold at an average price of $119.55, for a transaction totalling $298,875.00.

Who are Intellia Therapeutics' active insiders?

Intellia Therapeutics' insider roster includes John Crowley (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), and Laura Sepp-Lorenzino (EVP).

Are insiders buying or selling shares of Intellia Therapeutics?

In the last year, insiders at the sold shares 40 times. They sold a total of 2,344,862 shares worth mmore than $217,433,111.40. The most recent insider tranaction occured on October, 14th when David Lebwohl EVP bought 2,400 shares worth more than $308,256.00. Insiders at Intellia Therapeutics own 3.9 % of the company.

Information on this page was last updated on 10/14/2021.

John F. Crowley Insider Trading History at Intellia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2021Sell2,500$119.55$298,875.00View SEC Filing Icon  
10/5/2021Sell10,000$130.54$1,305,400.00View SEC Filing Icon  
See Full Table

John F. Crowley Buying and Selling Activity at Intellia Therapeutics

This chart shows John F Crowley's buying and selling at Intellia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intellia Therapeutics Company Overview

Intellia Therapeutics logo
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $130.79
Low: $129.53
High: $135.56

50 Day Range

MA: $149.07
Low: $120.71
High: $176.78

2 Week Range

Now: $130.79
Low: $23.49
High: $202.73


8,957 shs

Average Volume

1,599,373 shs

Market Capitalization

$9.61 billion

P/E Ratio


Dividend Yield



Undervalued Copper Stock could Be Set for Another 600% Run
Small Company, Big Profit Opportunity in America's Hottest Mining Spot

This may be one of the most undervalued copper stocks on the market
Get the insider scoop!